Semin intervent Radiol 2014; 31(01): 091-097
DOI: 10.1055/s-0033-1363848
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Immunologics and Chemotherapeutics for Renal Cell Carcinoma

Elan Diamond
1   Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College
,
Jamie Riches
2   Department of Medicine, St. Luke's-Roosevelt Hospital Center, New York, New York
,
Bishoy Faltas
1   Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College
,
Scott T. Tagawa
1   Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College
,
David M. Nanus
1   Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
20. Februar 2014 (online)

Abstract

Treatment of metastatic renal cell carcinoma remains a challenge for clinicians. Traditional chemotherapy is ineffective and immunotherapy with interleukin-2 is only occasionally beneficial. The development of numerous agents targeting vascular endothelial growth factor and mammalian target of rapamycin signaling pathways that have been studied in phase III trials have resulted in significant improvement in survival for patients with clear cell renal cell carcinoma. Currently available U.S. Food and Drug Administration-approved first line targeted agents include sunitinib, pazopanib, temsirolimus, and bevacizumab (with interferon), while axitinib, everolimus, and sorafenib are most extensively used following progression as second- or third line therapy. Attempts to augment the activity of these agents by combining them together or with chemotherapy or immunotherapy have not yet proven to improve outcomes. As a result, the sequential use of single agents remains the current standard of care.

 
  • References

  • 1 Chin AI, Lam JS, Figlin RA, Belldegrun AS. Surveillance strategies for renal cell carcinoma patients following nephrectomy. Rev Urol 2006; 8 (1) 1-7
  • 2 SEER Cancer Statistics Review, 1975–2010. In: Howlader N, Noone A, Krapcho M. , et al, eds. Bethesda, MD: National Cancer Institute; 2013 . Available at: http://seer.cancer.gov/csr/1975_2010/ . Accessed June 12, 2013
  • 3 Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 1993; 71 (3, Suppl) 1098-1109
  • 4 Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005; (1) CD001425
  • 5 Pyrhönen S, Salminen E, Ruutu M , et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 1999; 17 (9) 2859-2867
  • 6 Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995; 13 (3) 688-696
  • 7 Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 2000; 6 (Suppl. 01) S55-S57
  • 8 McDermott DF, Ghebremichael MS, Signoretti S , et al. The high-dose aldesleukin (HD IL-2) “SELECT” trial in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol ASCO Annual Meeting Abstracts 2010; 28 (15, Suppl): 4514
  • 9 McDermott DF. Update on the application of interleukin-2 in the treatment of renal cell carcinoma. Clin Cancer Res 2007; 13 (2 Pt 2) 716s-720s
  • 10 Arjumand W, Sultana S. Role of VHL gene mutation in human renal cell carcinoma. Tumour Biol 2012; 33 (1) 9-16
  • 11 Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol 2004; 22 (24) 4991-5004
  • 12 Tory K, Brauch H, Linehan M , et al. Specific genetic change in tumors associated with von Hippel-Lindau disease. J Natl Cancer Inst 1989; 81 (14) 1097-1101
  • 13 Yang JC, Haworth L, Sherry RM , et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349 (5) 427-434
  • 14 Escudier B, Bellmunt J, Négrier S , et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 2010; 28 (13) 2144-2150
  • 15 Rini BI, Halabi S, Rosenberg JE , et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010; 28 (13) 2137-2143
  • 16 Escudier B, Eisen T, Stadler WM , et al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009; 27 (20) 3312-3318
  • 17 Escudier B, Szczylik C, Hutson TE , et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27 (8) 1280-1289
  • 18 Hutson TE, Lesovoy V, Al-Shukri S. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal cell carcinoma: a randomised open-label phase 3 trial. Lancet Oncol 2013; 14 (Suppl. 13) 1287-1294
  • 19 Motzer RJ, Michaelson MD, Redman BG , et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24 (1) 16-24
  • 20 Motzer RJ, Rini BI, Bukowski RM , et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006; 295 (21) 2516-2524
  • 21 Motzer RJ, Hutson TE, Tomczak P , et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27 (22) 3584-3590
  • 22 Dudek AZ, Raza A, Chi M , et al. Brain metastases from renal cell carcinoma in the era of tyrosine kinase inhibitors. Clin Genitourin Cancer 2013; 11 (2) 155-160
  • 23 Motzer RJ, Hutson TE, Olsen MR , et al. Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol 2012; 30 (12) 1371-1377
  • 24 Hutson TE, Davis ID, Machiels JP , et al. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol 2010; 28 (3) 475-480
  • 25 Sternberg CN, Davis ID, Mardiak J , et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010; 28 (6) 1061-1068
  • 26 Motzer RJ, Hutson TE, Cella D , et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 2013; 369 (8) 722-731
  • 27 Rixe O, Bukowski RM, Michaelson MD , et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 2007; 8 (11) 975-984
  • 28 Rini BI, Wilding G, Hudes G , et al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 2009; 27 (27) 4462-4468
  • 29 Rini BI, Escudier B, Tomczak P , et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011; 378 (9807) 1931-1939
  • 30 Rini BI, Melichar B, Ueda T , et al. Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial. Lancet Oncol 2013; 14: 1233-1242
  • 31 Hudes G, Carducci M, Tomczak P , et al; Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356 (22) 2271-2281
  • 32 Dutcher JP, de Souza P, McDermott D , et al. Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol 2009; 26 (2) 202-209
  • 33 Hutson TE, Escudier B, Esteban E , et al. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2013;
  • 34 Motzer RJ, Escudier B, Oudard S , et al; RECORD-1 Study Group. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372 (9637) 449-456
  • 35 Kuebler JP, Hogan TF, Trump DL, Bryan GT. Phase II study of continuous 5-day vinblastine infusion in renal adenocarcinoma. Cancer Treat Rep 1984; 68 (6) 925-926
  • 36 Hrushesky WJ, von Roemeling R, Lanning RM, Rabatin JT. Circadian-shaped infusions of floxuridine for progressive metastatic renal cell carcinoma. J Clin Oncol 1990; 8 (9) 1504-1513
  • 37 Desai AA, Vogelzang NJ, Rini BI, Ansari R, Krauss S, Stadler WM. A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma. Cancer 2002; 95 (8) 1629-1636
  • 38 George CM, Vogelzang NJ, Rini BI, Geoffroy FJ, Kollipara P, Stadler WM. A phase II trial of weekly intravenous gemcitabine and cisplatin with continuous infusion fluorouracil in patients with metastatic renal cell carcinoma. Ann Oncol 2002; 13 (1) 116-120
  • 39 Bennouna J, Delva R, Gomez F , et al. A phase II study with 5-fluorouracil, folinic acid and oxaliplatin (FOLFOX-4 regimen) in patients with metastatic renal cell carcinoma. Oncology 2003; 64 (1) 25-27
  • 40 Haas NB, Lin X, Manola J , et al. A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802. Med Oncol 2012; 29 (2) 761-767
  • 41 Nanus DM, Garino A, Milowsky MI, Larkin M, Dutcher JP. Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer 2004; 101 (7) 1545-1551
  • 42 Fosså SD, Raabe N, Moe B. Recombinant interferon-alpha with or without vinblastine in metastatic renal carcinoma. Results of a randomised phase II study. Br J Urol 1989; 64 (5) 468-471
  • 43 Rizzo M, Bartoletti R, Selli C, Sicignano A, Criscuolo D. Interferon alpha-2a and vinblastine in the treatment of metastatic renal carcinoma. Eur Urol 1989; 16 (4) 271-277
  • 44 Neidhart JA, Anderson SA, Harris JE , et al. Vinblastine fails to improve response of renal cancer to interferon alfa-n1: high response rate in patients with pulmonary metastases. J Clin Oncol 1991; 9 (5) 832-836
  • 45 Pyrhönen S, Salminen E, Ruutu M , et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 1999; 17 (9) 2859-2867
  • 46 Ellerhorst JA, Sella A, Amato RJ , et al. Phase II trial of 5-fluorouracil, interferon-alpha and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma. Cancer 1997; 80 (11) 2128-2132
  • 47 Kirchner GI, Franzke A, Buer J , et al. Pharmacokinetics of recombinant human interleukin-2 in advanced renal cell carcinoma patients following subcutaneous application. Br J Clin Pharmacol 1998; 46 (1) 5-10
  • 48 Joffe JK, Banks RE, Forbes MA , et al. A phase II study of interferon-alpha, interleukin-2 and 5-fluorouracil in advanced renal carcinoma: clinical data and laboratory evidence of protease activation. Br J Urol 1996; 77 (5) 638-649
  • 49 Dutcher JP, Fisher RI, Weiss G , et al. Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study. Cancer J Sci Am 1997; 3 (3) 157-162
  • 50 Gitlitz BJ, Belldegrun A, Figlin RA. Immunotherapy and gene therapy. Semin Urol Oncol 1996; 14 (4) 237-243
  • 51 Atzpodien J, Kirchner H, Jonas U , et al; Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol 2004; 22 (7) 1188-1194
  • 52 Hongyun L, Zhihong C, Xiangqing Y , et al. Phase II study of sorafenib combined with gemcitabine and 5-fluorouracil in patients with metastatic renal cell carcinoma: preliminary results. J Clin Oncol 2009; 27 (suppl): abstr e16093
  • 53 Tagawa ST, Milowsky MI, Jeske S , et al. A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981. Am J Clin Oncol 2011; 34 (5) 443-448
  • 54 Tagawa ST, Saran A, Akhtar NH , et al. Final phase II results of NCI 6981: a phase I/II study of sorafenib plus gemcitabine and capecitabine for advanced renal cell carcinoma. J Clin Oncol 2011; 29 (suppl): abstr e15165
  • 55 Bellmunt J, Trigo JM, Calvo E , et al. Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06). Lancet Oncol 2010; 11 (4) 350-357
  • 56 Pandya SS, Mier JW, McDermott DF, Cho DC. Addition of gemcitabine at the time of sunitinib resistance in metastatic renal cell cancer. BJU Int 2011; 108 (8 Pt 2) E245-E249
  • 57 Michaelson MD, Zhu AX, Ryan DP , et al. Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study. Br J Cancer 2013; 108 (7) 1393-1401
  • 58 Suarez C, Gallardo E, Rodon Ahnert J , et al. Phase I study of sunitinib in combination with gemcitabine/capecitabine for the first-line treatment of metastatic or unresectable renal cell carcinoma. ASCO Meeting Abstracts 2011; 29: e15095
  • 59 Jonasch E, Lal LS, Atkinson BJ , et al. Treatment of metastatic renal carcinoma patients with the combination of gemcitabine, capecitabine and bevacizumab at a tertiary cancer centre. BJU Int 2011; 107 (5) 741-747
  • 60 Staehler M, Haseke N, Roosen A , et al. Sorafenib after combination therapy with gemcitabine plus doxorubicine in patients with sarcomatoid renal cell carcinoma: a prospective evaluation. Eur J Med Res 2010; 15: 287-291
  • 61 Michaelson MD, McDermott DF, Atkins MB , et al. Combination of antiangiogenic therapy and cytotoxic chemotherapy for sarcomatoid renal cell carcinoma. J Clin Oncol 2013; 31 (suppl):abstr 4512
  • 62 Jonasch E, Lal LS, Atkinson BJ , et al. Treatment of metastatic renal carcinoma patients with the combination of gemcitabine, capecitabine and bevacizumab at a tertiary cancer centre. BJU Int 2011; 107 (5) 741-747
  • 63 Chung EK, Posadas EM, Kasza K , et al. A phase II trial of gemcitabine, capecitabine, and bevacizumab in metastatic renal carcinoma. Am J Clin Oncol 2011; 34 (2) 150-154
  • 64 Thompson RH, Gillett MD, Cheville JC , et al. Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A 2004; 101 (49) 17174-17179
  • 65 Cho DC, Sosman JA, Sznol M , et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2013; 31 (suppl):abstr 4505
  • 66 Drake CG, McDermott DF, Sznol M , et al. Survival, safety, and response duration results of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in a phase I trial in patients with previously treated metastatic renal cell carcinoma (mRCC): long-term patient follow-up. J Clin Oncol 2013; 31 (suppl):abstr 4514
  • 67 Amin A, Ernstoff MS, Infante JR , et al. A phase I study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) in combination with sunitinib, pazopanib, or ipilimumab in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2013; 31 (suppl):abstr TPS4593
  • 68 Liu W, Shen SM, Zhao XY, Chen GQ. Targeted genes and interacting proteins of hypoxia inducible factor-1. Int J Biochem Mol Biol 2012; 3 (2) 165-178